PPCB (Propanc Biopharma) Debt-to-Asset : 0.04 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PPCB Propanc Biopharma Inc PPCB
29 GF Score
Price $1.51
! 2 Warning Signs
View Full Analysis

What is Propanc Biopharma Debt-to-Asset?

Propanc Biopharma PPCB +3.08% 29 Debt-to-Asset is 0.04 as of Mar. 2026. GuruFocus rates PPCB with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

Propanc Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.54 Mil. Propanc Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.03 Mil. Propanc Biopharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2026 was $14.33 Mil. Propanc Biopharma's debt to asset for the quarter that ended in Mar. 2026 was 0.04.

Propanc Biopharma  (NAS:PPCB) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Propanc Biopharma Debt-to-Asset Related Terms

Propanc Biopharma Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Propanc Biopharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Propanc Biopharma Debt-to-Asset Chart

Propanc Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.31 12.68 9.10 13.18 0.09

Propanc Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.09 0.04 0.04 0.04

PPCB vs GRI, BGMS, SPRC: Debt-to-Asset Comparison

For the Biotechnology subindustry, Propanc Biopharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Propanc Biopharma Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Propanc Biopharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Propanc Biopharma's Debt-to-Asset falls into.


PPCB
29GF Score
Propanc Biopharma Inc PPCB
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Propanc Biopharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Propanc Biopharma's Debt-to-Asset for the fiscal year that ended in Jun. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(1.58 + 0.147) / 19.632
=0.09

Propanc Biopharma's Debt-to-Asset for the quarter that ended in Mar. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.544 + 0.03) / 14.334
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.04 mean?
Propanc Biopharma (PPCB) has a Debt-to-Asset of 0.04 as of Mar. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Propanc Biopharma and its competitors.
Is Propanc Biopharma's Debt-to-Asset too high?
Propanc Biopharma's current Debt-to-Asset is 0.04. Overall, Propanc Biopharma has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Propanc Biopharma's Debt-to-Asset compare to GRI and BGMS?
Propanc Biopharma's Debt-to-Asset of 0.04 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Propanc Biopharma and its competitors. Propanc Biopharma's current Debt-to-Asset is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Propanc Biopharma stock overvalued right now?
Propanc Biopharma (PPCB) has a current Debt-to-Asset of 0.04. The current Debt-to-Asset is 0.04. Propanc Biopharma's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Propanc Biopharma (PPCB), the current Debt-to-Asset is 0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Propanc Biopharma Business Description

Address 302, 6 Butler Street, Cambwerwell, VIC, AUS, 3124
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
29GF Score

Get the complete analysis for PPCB

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.51
Price